Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain

被引：0
|
作者：
Eliazar Sabater
Armando López-Guillermo
Antonio Rueda
Antonio Salar
Itziar Oyagüez
Juan Manuel Collar
机构：
[1] Pharmacoeconomics and Outcomes Research Iberia,Haematology Department
[2] Hospital Clinic,Oncology Department
[3] Hospital Costa del Sol,Haematology Department
[4] Hospital del Mar,Medical Department
[5] Mundipharma Pharmaceuticals,undefined
来源：
Applied Health Economics and Health Policy | 2016年 / 14卷
关键词：
Follicular Lymphoma; Bendamustine; Bayesian Information Criterion; Progression State; Spanish National Health System;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：465 / 477
页数：12
相关论文
共 50 条
  • [31] Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
    Zucca, Emanuele
    Rondeau, Stephanie
    Vanazzi, Anna
    Ostenstad, Bjorn
    Mey, Ulrich J. M.
    Rauch, Daniel
    Wahlin, Bjorn E.
    Hitz, Felicitas
    Hernberg, Micaela
    Johansson, Ann-Sofie
    Brown, Peter de Nully
    Hagberg, Hans
    Ferreri, Andres J. M.
    Lohri, Andreas
    Novak, Urban
    Zander, Thilo
    Bersvendsen, Hanne
    Bargetzi, Mario
    Mingrone, Walter
    Krasniqi, Fatime
    Dirnhofer, Stefan
    Hayoz, Stefanie
    Hawle, Hanne
    Vilei, Simona Berardi
    Ghielmini, Michele
    Kimby, Eva
    Caspar, Clemens
    Koberle, Dieter
    Novak, Urban
    Zenhausern, Reinhard
    Jost, Lorenz M.
    Mach, Nicolas
    Voegeli, Michele
    Tscherry, Georg
    Fischer, Natalie
    Burkhard, Roger
    Schmid, Mathias
    Panagiotis, Samaras
    Munksgaard, Lars
    Hernberg, Micaela
    Vasala, Kaija
    Lehtinen, Tuula
    Jyrkkio, Sirkku
    Ekanger, Roald
    Rolke, Jurgen
    Meyer, Peter
    Maisenholder, Martin
    Eidem, Monika
    Radlund, Anders
    Lagerlof, Ingemar
    BLOOD, 2019, 134 (04) : 353 - 362
  • [32] RITUXIMAB-BENDAMUSTINE AS FIRST LINE OF TREATMENT IN PATIENTS WITH FOLLICULAR LYMPHOMA. EXPERIENCE OF ONE CENTER
    Melian Haridian, De la Nuez
    Henriquez Hugo, Luzardo
    Cabrera Alexia, Suarez
    Gonzalez Paula, Fernandez-Caldas
    Cruz Naylen, Cruz
    Borrego Asuncion, Borrero
    Juan Francisco, Lopez Rodriguez
    Curbelo Alejandro, Morales
    De La Cruz Marcos, Cabezas
    Maria Teresa, Gomez Casares
    HAEMATOLOGICA, 2021, 106 (10) : 296 - 297
  • [33] Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma
    De la Cruz Vicente, Fatima
    Carrillo-Cruz, Estrella
    Sole Rodriguez, Maria
    Marin Niebla, Ana
    Martino Galiana, Maria Luz
    Falantes Gonzalez, Jose
    Montero Cuadrado, Isabel
    Gonzalez Campos, Jose
    Espigado Tocino, Ildefonso
    Rios-Herranz, Eduardo
    Antonio Perez-Simon, Jose
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (06) : 469 - 475
  • [34] Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
    Gwladys Claustre
    Coralie Boulanger
    Frédéric Maloisel
    Nelly Etienne-Selloum
    Luc-Matthieu Fornecker
    Eric Durot
    Florian Slimano
    Véronique Graff
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1883 - 1893
  • [35] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Zhou, Yangying
    Peng, Libo
    ADVANCES IN THERAPY, 2022, 39 (06) : 2614 - 2629
  • [36] Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
    Ye, Zhuo-miao
    Xu, Zhe
    Li, Huan
    Li, Qian
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [37] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Youwen Zhu
    Kun Liu
    Dong Ding
    Yangying Zhou
    Libo Peng
    Advances in Therapy, 2022, 39 : 2614 - 2629
  • [38] Cost-effectiveness analysis of first-line HAART
    Maggiolo, F.
    Di Matteo, S.
    Masini, G.
    Astuti, N.
    Di Filippo, E.
    Bernardini, C.
    Soavi, L.
    Colombo, G.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 69 - 70
  • [39] Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
    Claustre, Gwladys
    Boulanger, Coralie
    Maloisel, Frederic
    Etienne-Selloum, Nelly
    Fornecker, Luc-Matthieu
    Durot, Eric
    Slimano, Florian
    Graff, Veronique
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (05) : 1883 - 1893
  • [40] A multicenter randomized trial of Fludarabine and Mitoxantrone (FM) plus Rituximab versus CHOP plus Rituximab as first-line treatment in patients with follicular lymphoma (FL).
    Zinzani, PL
    BLOOD, 2002, 100 (11) : 93A - 93A
12345